CEA
Umda wokufumanisa: ≤ 1.0 ng / mL;
Uluhlu lweMila: 1-500 ng / mL;
I-coefficient yokulungelelanisa yomgca R ≥ 0.990;
Ukuchaneka: ngaphakathi kwe-batch CV ngu ≤ 15%;phakathi kweebhetshi iCV yi ≤ 20%;
Ukuchaneka: ukutenxa okunxulumeneyo kweziphumo zomlinganiselo akusayi kudlula ± 15% xa isikali sokuchaneka esilungiswe ngumgangatho wesizwe we-CEA okanye isilinganisi sokuchaneka esisemgangathweni sivavanywa.
1. Gcina i-detector buffer ku-2～30℃.Isithinteli sizinzile ukuya kwiinyanga ezili-18.
2. Gcina i-Aehealth Ferritin Rapid Quantitative test cassette kwi-2～30℃, ubomi beshelufu bufikelela kwiinyanga ezili-18.
3. Ikhasethi yovavanyo kufuneka isetyenziswe kwiyure enye emva kokuvula ipakethi.
I-CEA (i-Carcinoembryonic Antigen), i-cell-surface ye-200 KD glycoprotein, idla ngokuveliswa ngexesha lokukhula kwe-fetus kodwa inyamalale okanye ibe phantsi kakhulu egazini labantu abadala abaphilileyo ngenxa yokuba ukuhlanganiswa kwale proteni kuyeka ngaphambi kokuzalwa.Nangona kunjalo, amanqanaba anyukileyo anokubakho kwi-colorectum, indawo yesisu, isifuba, i-ovary, isibindi, imiphunga, i-pancreas, i-biliary kunye ne-medullary thyroid carcinoma, kunye nezinye iimeko ezinobungozi ezifana nokutshaya, isifo sesibindi esivuthayo, i-gastritis engapheliyo, i-peptic ulcer, i-cirrhosis. , i-hepatitis kunye ne-pancreatitis.I-CEA isoloko isetyenziselwa ukubeka iliso kwizigulane ezinomhlaza, ngakumbi i-colorectal carcinoma, emva kotyando ukulinganisa impendulo kunyango kunye nokuba isifo siyaphinda.Xa inqanaba le-CEA liphezulu ngokungaqhelekanga phambi kotyando okanye olunye unyango, kulindeleke ukuba libuyele kwisiqhelo emva kotyando oluyimpumelelo lokususa i-carcinoma.Ukunyuka kwenqanaba le-CEA kubonisa ukuqhubela phambili okanye ukuphindaphinda komhlaza.